ID   B3AT_HUMAN              Reviewed;         911 AA.
AC   P02730; G4V2I6; P78487; Q1ZZ45; Q4KKW9; Q4VB84; Q9UCY7; Q9UDJ1;
DT   21-JUL-1986, integrated into UniProtKB/Swiss-Prot.
DT   01-APR-1990, sequence version 3.
DT   10-MAY-2017, entry version 227.
DE   RecName: Full=Band 3 anion transport protein;
DE   AltName: Full=Anion exchange protein 1;
DE            Short=AE 1;
DE            Short=Anion exchanger 1;
DE   AltName: Full=Solute carrier family 4 member 1;
DE   AltName: CD_antigen=CD233;
GN   Name=SLC4A1; Synonyms=AE1, DI, EPB3;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RC   TISSUE=Blood;
RX   PubMed=3223947; DOI=10.1042/bj2560703;
RA   Tanner M.J.A., Martin P.G., High S.;
RT   "The complete amino acid sequence of the human erythrocyte membrane
RT   anion-transport protein deduced from the cDNA sequence.";
RL   Biochem. J. 256:703-712(1988).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RX   PubMed=2594752; DOI=10.1073/pnas.86.23.9089;
RA   Lux S.E., John K.M., Kopito R.R., Lodish H.F.;
RT   "Cloning and characterization of band 3, the human erythrocyte anion-
RT   exchange protein (AE1).";
RL   Proc. Natl. Acad. Sci. U.S.A. 86:9089-9093(1989).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA], AND VARIANT ALA-38.
RX   PubMed=16252102; DOI=10.1007/s00467-005-2061-z;
RA   Choo K.E., Nicoli T.K., Bruce L.J., Tanner M.J., Ruiz-Linares A.,
RA   Wrong O.M.;
RT   "Recessive distal renal tubular acidosis in Sarawak caused by AE1
RT   mutations.";
RL   Pediatr. Nephrol. 21:212-217(2006).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RC   TISSUE=Blood;
RA   Hsu K., Huang S.-Y., Chi N., Lin M.;
RT   "Novel anion exchanger-1 expression in Southeast Asian populations.";
RL   Submitted (SEP-2009) to the EMBL/GenBank/DDBJ databases.
RN   [5]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND VARIANTS ALA-38; GLU-56;
RP   LYS-508 AND ILE-862.
RG   SeattleSNPs variation discovery resource;
RL   Submitted (MAY-2005) to the EMBL/GenBank/DDBJ databases.
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G., Florea L., Halpern A.L.,
RA   Mobarry C.M., Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R.,
RA   Flanigan M.J., Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V.,
RA   Hannenhalli S., Turner R., Yooseph S., Lu F., Nusskern D.R.,
RA   Shue B.C., Zheng X.H., Zhong F., Delcher A.L., Huson D.H.,
RA   Kravitz S.A., Mouchard L., Reinert K., Remington K.A., Clark A.G.,
RA   Waterman M.S., Eichler E.E., Adams M.D., Hunkapiller M.W., Myers E.W.,
RA   Venter J.C.;
RL   Submitted (SEP-2005) to the EMBL/GenBank/DDBJ databases.
RN   [7]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA], AND VARIANT HIS-27.
RC   TISSUE=Cerebellum;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [8]
RP   PROTEIN SEQUENCE OF 1-199; 220-292 AND 347-370, AND ACETYLATION AT
RP   MET-1.
RX   PubMed=2790053; DOI=10.1016/0167-4838(89)90116-7;
RA   Yannoukakos D., Vasseur C., Blouquit Y., Bursaux E., Wajcman H.;
RT   "Primary structure of the cytoplasmic domain of human erythrocyte
RT   protein band 3. Comparison with its sequence in the mouse.";
RL   Biochim. Biophys. Acta 998:43-49(1989).
RN   [9]
RP   PROTEIN SEQUENCE OF 1-201.
RX   PubMed=6345535;
RA   Kaul R.K., Murthy S.N.P., Reddy A.G., Steck T.L., Kohler H.;
RT   "Amino acid sequence of the N alpha-terminal 201 residues of human
RT   erythrocyte membrane band 3.";
RL   J. Biol. Chem. 258:7981-7990(1983).
RN   [10]
RP   PROTEIN SEQUENCE OF 1-3.
RX   PubMed=701248;
RA   Drickamer L.K.;
RT   "Orientation of the band 3 polypeptide from human erythrocyte
RT   membranes. Identification of NH2-terminal sequence and site of
RT   carbohydrate attachment.";
RL   J. Biol. Chem. 253:7242-7248(1978).
RN   [11]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 66-180 (ISOFORM 2), SUBCELLULAR
RP   LOCATION, AND TISSUE SPECIFICITY.
RX   PubMed=7506871;
RA   Kollert-Jons A., Wagner S., Hubner S., Appelhans H., Drenckhahn D.;
RT   "Anion exchanger 1 in human kidney and oncocytoma differs from
RT   erythroid AE1 in its NH2 terminus.";
RL   Am. J. Physiol. 265:F813-F821(1993).
RN   [12]
RP   PROTEIN SEQUENCE OF 361-372; 390-399; 604-613; 632-639; 647-656;
RP   699-729; 731-743; 761-781 AND 818-826, AND SYNTHESIS OF 646-656 AND
RP   817-827.
RX   PubMed=1527044;
RA   Kang D., Okubo K., Hamasaki N., Kuroda N., Shiraki H.;
RT   "A structural study of the membrane domain of band 3 by tryptic
RT   digestion. Conformational change of band 3 in situ induced by alkali
RT   treatment.";
RL   J. Biol. Chem. 267:19211-19217(1992).
RN   [13]
RP   PROTEIN SEQUENCE OF 559-630.
RX   PubMed=6615451; DOI=10.1042/bj2130577;
RA   Brock C.J., Tanner M.J.A., Kempf C.;
RT   "The human erythrocyte anion-transport protein. Partial amino acid
RT   sequence, conformation and a possible molecular mechanism for anion
RT   exchange.";
RL   Biochem. J. 213:577-586(1983).
RN   [14]
RP   PROTEIN SEQUENCE OF 665-688, AND ROLE OF GLU-681.
RX   PubMed=1352774;
RA   Jennings M.L., Smith J.S.;
RT   "Anion-proton cotransport through the human red blood cell band 3
RT   protein. Role of glutamate 681.";
RL   J. Biol. Chem. 267:13964-13971(1992).
RN   [15]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 757-778, AND VARIANT SPH4 ASP-771.
RX   PubMed=8547122; DOI=10.1111/j.1365-2141.1995.tb05393.x;
RA   Maillet P., Vallier A., Reinhart W.H., Wyss E.J., Ott P., Texier P.,
RA   Baklouti F., Tanner M.J.A., Delaunay J., Alloisio N.;
RT   "Band 3 Chur: a variant associated with band 3-deficient hereditary
RT   spherocytosis and substitution in a highly conserved position of
RT   transmembrane segment 11.";
RL   Br. J. Haematol. 91:804-810(1995).
RN   [16]
RP   PROTEIN SEQUENCE OF 834-911.
RX   PubMed=3372523;
RA   Kawano Y., Okubo K., Tokunaga F., Miyata T., Iwanaga S., Hamasaki N.;
RT   "Localization of the pyridoxal phosphate binding site at the COOH-
RT   terminal region of erythrocyte band 3 protein.";
RL   J. Biol. Chem. 263:8232-8238(1988).
RN   [17]
RP   PHOSPHORYLATION AT TYR-8; TYR-21 AND TYR-46.
RX   PubMed=1998697; DOI=10.1016/0005-2736(91)90291-F;
RA   Yannoukakos D., Vasseur C., Piau J.-P., Wajcman H., Bursaux E.;
RT   "Phosphorylation sites in human erythrocyte band 3 protein.";
RL   Biochim. Biophys. Acta 1061:253-266(1991).
RN   [18]
RP   PALMITOYLATION AT CYS-843.
RX   PubMed=1885574;
RA   Okubo K., Hamasaki N., Hara K., Kageura M.;
RT   "Palmitoylation of cysteine 69 from the COOH-terminal of band 3
RT   protein in the human erythrocyte membrane. Acylation occurs in the
RT   middle of the consensus sequence of F--I-IICLAVL found in band 3
RT   protein and G2 protein of Rift Valley fever virus.";
RL   J. Biol. Chem. 266:16420-16424(1991).
RN   [19]
RP   INTERACTION WITH ANK1.
RX   PubMed=7665627; DOI=10.1074/jbc.270.37.22050;
RA   Michaely P., Bennett V.;
RT   "The ANK repeats of erythrocyte ankyrin form two distinct but
RT   cooperative binding sites for the erythrocyte anion exchanger.";
RL   J. Biol. Chem. 270:22050-22057(1995).
RN   [20]
RP   GLYCOSYLATION AT ASN-642.
RX   PubMed=10861210; DOI=10.1042/0264-6021:3490051;
RA   Li J., Quilty J., Popov M., Reithmeier R.A.;
RT   "Processing of N-linked oligosaccharide depends on its location in the
RT   anion exchanger, AE1, membrane glycoprotein.";
RL   Biochem. J. 349:51-57(2000).
RN   [21]
RP   PHOSPHORYLATION AT TYR-8; TYR-21; TYR-359 AND TYR-904.
RX   PubMed=10942405;
RA   Brunati A.M., Bordin L., Clari G., James P., Quadroni M., Baritono E.,
RA   Pinna L.A., Donella-Deana A.;
RT   "Sequential phosphorylation of protein band 3 by Syk and Lyn tyrosine
RT   kinases in intact human erythrocytes: identification of primary and
RT   secondary phosphorylation sites.";
RL   Blood 96:1550-1557(2000).
RN   [22]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P.,
RA   Buerckstuemmer T., Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
RN   [23]
RP   SUBCELLULAR LOCATION, TISSUE SPECIFICITY, INTERACTION WITH STOM, AND
RP   SUBUNIT.
RX   PubMed=23219802; DOI=10.1016/j.bbamem.2012.11.030;
RA   Rungaldier S., Oberwagner W., Salzer U., Csaszar E., Prohaska R.;
RT   "Stomatin interacts with GLUT1/SLC2A1, band 3/SLC4A1, and aquaporin-1
RT   in human erythrocyte membrane domains.";
RL   Biochim. Biophys. Acta 1828:956-966(2013).
RN   [24]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Liver;
RX   PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014;
RA   Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D.,
RA   Wang L., Ye M., Zou H.;
RT   "An enzyme assisted RP-RPLC approach for in-depth analysis of human
RT   liver phosphoproteome.";
RL   J. Proteomics 96:253-262(2014).
RN   [25]
RP   INTERACTION WITH TM139.
RX   PubMed=26049106; DOI=10.1016/j.bbrc.2015.05.128;
RA   Nuiplot N.O., Junking M., Duangtum N., Khunchai S., Sawasdee N.,
RA   Yenchitsomanus P.T., Akkarapatumwong V.;
RT   "Transmembrane protein 139 (TMEM139) interacts with human kidney
RT   isoform of anion exchanger 1 (kAE1).";
RL   Biochem. Biophys. Res. Commun. 463:706-711(2015).
RN   [26]
RP   STRUCTURE BY ELECTRON CRYOMICROSCOPY.
RX   PubMed=8508760;
RA   Wang D.N., Kuehlbrandt W., Sarabia V.E., Reithmeier R.A.F.;
RT   "Two-dimensional structure of the membrane domain of human band 3, the
RT   anion transport protein of the erythrocyte membrane.";
RL   EMBO J. 12:2233-2239(1993).
RN   [27]
RP   STRUCTURE BY ELECTRON CRYOMICROSCOPY.
RX   PubMed=8045253;
RA   Wang D.N., Sarabia V.E., Reithmeier R.A.F., Kuehlbrandt W.;
RT   "Three-dimensional map of the dimeric membrane domain of the human
RT   erythrocyte anion exchanger, Band 3.";
RL   EMBO J. 13:3230-3235(1994).
RN   [28]
RP   STRUCTURE BY NMR OF 405-424 AND 436-456.
RX   PubMed=8168533; DOI=10.1111/j.1432-1033.1994.tb18757.x;
RA   Gargaro A.R., Bloomberg G.B., Dempsey C.E., Murray M., Tanner M.J.A.;
RT   "The solution structures of the first and second transmembrane-
RT   spanning segments of band 3.";
RL   Eur. J. Biochem. 221:445-454(1994).
RN   [29]
RP   STRUCTURE BY NMR OF 1-16.
RX   PubMed=8527430; DOI=10.1021/bi00051a005;
RA   Schneider M.L., Post C.B.;
RT   "Solution structure of a band 3 peptide inhibitor bound to aldolase: a
RT   proposed mechanism for regulating binding by tyrosine
RT   phosphorylation.";
RL   Biochemistry 34:16574-16584(1995).
RN   [30]
RP   STRUCTURE BY NMR OF 1-16.
RX   PubMed=9454576; DOI=10.1021/bi971445b;
RA   Eisenmesser E.Z., Post C.B.;
RT   "Insights into tyrosine phosphorylation control of protein-protein
RT   association from the NMR structure of a band 3 peptide inhibitor bound
RT   to glyceraldehyde-3-phosphate dehydrogenase.";
RL   Biochemistry 37:867-877(1998).
RN   [31]
RP   STRUCTURE BY NMR OF 389-430.
RX   PubMed=9765907; DOI=10.1042/bst0260516;
RA   Chambers E.J., Askin D., Bloomberg G.B., Ring S.M., Tanner M.J.;
RT   "Studies on the structure of a transmembrane region and a cytoplasmic
RT   loop of the human red cell anion exchanger.";
RL   Biochem. Soc. Trans. 26:516-520(1998).
RN   [32]
RP   STRUCTURE BY NMR OF 803-835.
RX   PubMed=9709005; DOI=10.1021/bi973158d;
RA   Askin D., Bloomberg G.B., Chambers E.J., Tanner M.J.;
RT   "NMR solution structure of a cytoplasmic surface loop of the human red
RT   cell anion transporter, band 3.";
RL   Biochemistry 37:11670-11678(1998).
RN   [33]
RP   X-RAY CRYSTALLOGRAPHY (2.6 ANGSTROMS) OF 1-379, AND SUBUNIT.
RX   PubMed=11049968;
RA   Zhang D., Kiyatkin A., Bolin J.T., Low P.S.;
RT   "Crystallographic structure and functional interpretation of the
RT   cytoplasmic domain of erythrocyte membrane band 3.";
RL   Blood 96:2925-2933(2000).
RN   [34]
RP   X-RAY CRYSTALLOGRAPHY (2.23 ANGSTROMS) OF 51-356, FUNCTION,
RP   SUBCELLULAR LOCATION, GLYCOSYLATION AT ASN-642, MUTAGENESIS OF GLU-85;
RP   ARG-283; ASN-642 AND GLU-681, AND CHARACTERIZATION OF VARIANT
RP   ACANTHOCYTOSIS LEU-868.
RX   PubMed=24121512; DOI=10.1074/jbc.M113.511865;
RA   Shnitsar V., Li J., Li X., Calmettes C., Basu A., Casey J.R.,
RA   Moraes T.F., Reithmeier R.A.;
RT   "A substrate access tunnel in the cytosolic domain is not an essential
RT   feature of the solute carrier 4 (SLC4) family of bicarbonate
RT   transporters.";
RL   J. Biol. Chem. 288:33848-33860(2013).
RN   [35]
RP   X-RAY CRYSTALLOGRAPHY (3.50 ANGSTROMS), TISSUE SPECIFICITY,
RP   SUBCELLULAR LOCATION, TOPOLOGY, AND GLYCOSYLATION.
RX   PubMed=26542571; DOI=10.1126/science.aaa4335;
RA   Arakawa T., Kobayashi-Yurugi T., Alguel Y., Iwanari H., Hatae H.,
RA   Iwata M., Abe Y., Hino T., Ikeda-Suno C., Kuma H., Kang D., Murata T.,
RA   Hamakubo T., Cameron A.D., Kobayashi T., Hamasaki N., Iwata S.;
RT   "Crystal structure of the anion exchanger domain of human erythrocyte
RT   band 3.";
RL   Science 350:680-684(2015).
RN   [36]
RP   VARIANT MEMPHIS GLU-56.
RX   PubMed=1678289;
RA   Yannoukakos D., Vasseur C., Driancourt C., Blouquit Y., Delauney J.,
RA   Wajcman H., Bursaux E.;
RT   "Human erythrocyte band 3 polymorphism (band 3 Memphis):
RT   characterization of the structural modification (Lys 56-->Glu) by
RT   protein chemistry methods.";
RL   Blood 78:1117-1120(1991).
RN   [37]
RP   VARIANT SAO 400-ALA--ALA-408 DEL, AND VARIANT MEMPHIS GLU-56.
RX   PubMed=1722314; DOI=10.1073/pnas.88.24.11022;
RA   Jarolim P., Palek J., Amato D., Hassan K., Sapak P., Nurse G.T.,
RA   Rubin H.L., Zhai S., Sahr K.E., Liu S.-C.;
RT   "Deletion in erythrocyte band 3 gene in malaria-resistant Southeast
RT   Asian ovalocytosis.";
RL   Proc. Natl. Acad. Sci. U.S.A. 88:11022-11026(1991).
RN   [38]
RP   VARIANT SPH4 ARG-327.
RX   PubMed=1378323;
RA   Jarolim P., Palek J., Rubin H.L., Prchal J.T., Korsgren C.,
RA   Cohen C.M.;
RT   "Band 3 Tuscaloosa: Pro-327-->Arg substitution in the cytoplasmic
RT   domain of erythrocyte band 3 protein associated with spherocytic
RT   hemolytic anemia and partial deficiency of protein 4.2.";
RL   Blood 80:523-529(1992).
RN   [39]
RP   VARIANT SAO 400-ALA--ALA-408 DEL, CHARACTERIZATION OF VARIANT SAO
RP   400-ALA--ALA-408 DEL, FUNCTION, SUBCELLULAR LOCATION, AND TISSUE
RP   SPECIFICITY.
RX   PubMed=1538405; DOI=10.1016/0022-2836(92)90254-H;
RA   Schofield A.E., Tanner M.J.A., Pinder J.C., Clough B., Bayley P.M.,
RA   Nash G.B., Dluzewski A.R., Reardon D.M., Cox T.M., Wilson R.J.M.,
RA   Gratzer W.B.;
RT   "Basis of unique red cell membrane properties in hereditary
RT   ovalocytosis.";
RL   J. Mol. Biol. 223:949-958(1992).
RN   [40]
RP   VARIANT ACANTHOCYTOSIS LEU-868.
RX   PubMed=8343110; DOI=10.1042/bj2930317;
RA   Bruce L.J., Kay M.M., Lawrence C., Tanner M.J.;
RT   "Band 3 HT, a human red-cell variant associated with acanthocytosis
RT   and increased anion transport, carries the mutation Pro-868-->Leu in
RT   the membrane domain of band 3.";
RL   Biochem. J. 293:317-320(1993).
RN   [41]
RP   VARIANT LYS-40.
RX   PubMed=8471774;
RA   Rybicki A.C., Qiu J.J.H., Musto S., Rosen N.L., Nagel R.L.,
RA   Schwartz R.S.;
RT   "Human erythrocyte protein 4.2 deficiency associated with hemolytic
RT   anemia and a homozygous 40 glutamic acid-->lysine substitution in the
RT   cytoplasmic domain of band 3 (band 3Montefiore).";
RL   Blood 81:2155-2165(1993).
RN   [42]
RP   VARIANTS BLOOD GROUP DI(A)/MEMPHIS-II GLU-56 AND LEU-854.
RX   PubMed=8206915;
RA   Bruce L.J., Anstee D.J., Spring F.A., Tanner M.J.;
RT   "Band 3 Memphis variant II. Altered stilbene disulfonate binding and
RT   the Diego (Dia) blood group antigen are associated with the human
RT   erythrocyte band 3 mutation Pro-854-->Leu.";
RL   J. Biol. Chem. 269:16155-16158(1994).
RN   [43]
RP   VARIANT BLOOD GROUP WR(A) LYS-658.
RX   PubMed=7812009;
RA   Bruce L.J., Ring S.M., Anstee D.J., Reid M.E., Wilkinson S.,
RA   Tanner M.J.;
RT   "Changes in the blood group Wright antigens are associated with a
RT   mutation at amino acid 658 in human erythrocyte band 3: a site of
RT   interaction between band 3 and glycophorin A under certain
RT   conditions.";
RL   Blood 85:541-547(1995).
RN   [44]
RP   VARIANTS SPH4 GLN-760; TRP-760; CYS-808 AND TRP-870.
RX   PubMed=7530501;
RA   Jarolim P., Rubin H.L., Brabec V., Chrobak L., Zolotarev A.S.,
RA   Alper S.L., Brugnara C., Wichterle H., Palek J.;
RT   "Mutations of conserved arginines in the membrane domain of erythroid
RT   band 3 lead to a decrease in membrane-associated band 3 and to the
RT   phenotype of hereditary spherocytosis.";
RL   Blood 85:634-640(1995).
RN   [45]
RP   VARIANTS SPH4 ASP-285; GLU-455; PRO-707; PRO-834 AND MET-837.
RX   PubMed=8943874;
RA   Jarolim P., Murray J.L., Rubin H.L., Taylor W.M., Prchal J.T.,
RA   Ballas S.K., Snyder L.M., Chrobak L., Melrose W.D., Brabec V.,
RA   Palek J.;
RT   "Characterization of 13 novel band 3 gene defects in hereditary
RT   spherocytosis with band 3 deficiency.";
RL   Blood 88:4366-4374(1996).
RN   [46]
RP   VARIANTS SPH4 CYS-518 AND MET-663 DEL, AND VARIANT LYS-40.
RX   PubMed=8640229; DOI=10.1038/ng0696-214;
RA   Eber S.W., Gonzalez J.M., Lux M.L., Scarpa A.L., Tse W.T.,
RA   Dornwell M., Herbers J., Kugler W., Oezcan R., Pekrun A.,
RA   Gallagher P.G., Schroeter W., Forget B.G., Lux S.E.;
RT   "Ankyrin-1 mutations are a major cause of dominant and recessive
RT   hereditary spherocytosis.";
RL   Nat. Genet. 13:214-218(1996).
RN   [47]
RP   VARIANTS SPH4 SER-147 AND MET-488.
RX   PubMed=9207478;
RA   Alloisio N., Texier P., Vallier A., Ribeiro M.L., Morle L., Bozon M.,
RA   Bursaux E., Maillet P., Goncalves P., Tanner M.J., Tamagnini G.,
RA   Delaunay J.;
RT   "Modulation of clinical expression and band 3 deficiency in hereditary
RT   spherocytosis.";
RL   Blood 90:414-420(1997).
RN   [48]
RP   VARIANT SPH4 ASN-783, AND VARIANTS ALA-38 AND MET-73.
RX   PubMed=9012689; DOI=10.1046/j.1365-2141.1997.8732504.x;
RA   Miraglia del Giudice E., Vallier A., Maillet P., Perrotta S.,
RA   Cutillo S., Iolascon A., Tanner M.J., Delaunay J., Alloisio N.;
RT   "Novel band 3 variants (bands 3 Foggia, Napoli I and Napoli II)
RT   associated with hereditary spherocytosis and band 3 deficiency: status
RT   of the D38A polymorphism within the EPB3 locus.";
RL   Br. J. Haematol. 96:70-76(1997).
RN   [49]
RP   VARIANTS SPH4 CYS-490 AND MET-837.
RX   PubMed=9233560; DOI=10.1046/j.1365-2141.1997.1893005.x;
RA   Dhermy D., Galand C., Bournier O., Boulanger L., Cynober T.,
RA   Schismanoff P.O., Bursaux E., Tchernia G., Boivin P., Garbarz M.;
RT   "Heterogenous band 3 deficiency in hereditary spherocytosis related to
RT   different band 3 gene defects.";
RL   Br. J. Haematol. 98:32-40(1997).
RN   [50]
RP   ERRATUM.
RA   Dhermy D., Galand C., Bournier O., Boulanger L., Cynober T.,
RA   Schismanoff P.O., Bursaux E., Tchernia G., Boivin P., Garbarz M.;
RL   Br. J. Haematol. 99:474-474(1997).
RN   [51]
RP   VARIANTS AD-DRTA CYS-589; HIS-589 AND PHE-613.
RX   PubMed=9312167; DOI=10.1172/JCI119694;
RA   Bruce L.J., Cope D.L., Jones G.K., Schofield A.E., Burley M.,
RA   Povey S., Unwin R.J., Wrong O., Tanner M.J.;
RT   "Familial distal renal tubular acidosis is associated with mutations
RT   in the red cell anion exchanger (Band 3, AE1) gene.";
RL   J. Clin. Invest. 100:1693-1707(1997).
RN   [52]
RP   VARIANTS BLOOD GROUPS RB(A); TR(A) AND WD(A).
RX   PubMed=9191821; DOI=10.1046/j.1537-2995.1997.37697335155.x;
RA   Jarolim P., Murray J.L., Rubin H.L., Smart E., Moulds J.M.;
RT   "Blood group antigens Rb(a), Tr(a), and Wd(a) are located in the third
RT   ectoplasmic loop of erythroid band 3.";
RL   Transfusion 37:607-615(1997).
RN   [53]
RP   VARIANT SPH4 ALA-837.
RX   PubMed=9973643; DOI=10.1159/000040904;
RA   Iwase S., Ideguchi H., Takao M., Horiguchi-Yamada J., Iwasaki M.,
RA   Takahara S., Sekikawa T., Mochizuki S., Yamada H.;
RT   "Band 3 Tokyo: Thr837-->Ala837 substitution in erythrocyte band 3
RT   protein associated with spherocytic hemolysis.";
RL   Acta Haematol. 100:200-203(1998).
RN   [54]
RP   VARIANTS BLOOD GROUPS BOW; BP(A); ELO; HG(A); MO(A); VG(A) AND WU.
RX   PubMed=9845551;
RA   Jarolim P., Rubin H.L., Zakova D., Storry J., Reid M.E.;
RT   "Characterization of seven low incidence blood group antigens carried
RT   by erythrocyte band 3 protein.";
RL   Blood 92:4836-4843(1998).
RN   [55]
RP   VARIANT DRTA-HA ASP-701.
RX   PubMed=9854053; DOI=10.1172/JCI4836;
RA   Tanphaichitr V.S., Sumboonnanonda A., Ideguchi H., Shayakul C.,
RA   Brugnara C., Takao M., Veerakul G., Alper S.L.;
RT   "Novel AE1 mutations in recessive distal renal tubular acidosis: loss-
RT   of-function is rescued by glycophorin A.";
RL   J. Clin. Invest. 102:2173-2179(1998).
RN   [56]
RP   VARIANTS AD-DRTA HIS-589 AND SER-589.
RX   PubMed=9600966; DOI=10.1073/pnas.95.11.6337;
RA   Karet F.E., Gainza F.J., Gyory A.Z., Unwin R.J., Wrong O.,
RA   Tanner M.J.A., Nayir A., Alpay H., Santos F., Hulton S.A.,
RA   Bakkaloglu A., Ozen S., Cunningham M.J., di Pietro A., Walker W.G.,
RA   Lifton R.P.;
RT   "Mutations in the chloride-bicarbonate exchanger gene AE1 cause
RT   autosomal dominant but not autosomal recessive distal renal tubular
RT   acidosis.";
RL   Proc. Natl. Acad. Sci. U.S.A. 95:6337-6342(1998).
RN   [57]
RP   VARIANTS BLOOD GROUP WU.
RX   PubMed=9709782; DOI=10.1046/j.1537-2995.1998.38898375513.x;
RA   Zelinski T., McManus K., Punter F., Moulds M., Coghlan G.;
RT   "A Gly565-->Ala substitution in human erythroid band 3 accounts for
RT   the Wu blood group polymorphism.";
RL   Transfusion 38:745-748(1998).
RN   [58]
RP   VARIANT SPH4 HIS-490.
RX   PubMed=10580570;
RA   Lima P.R.M., Sales T.S.I., Costa F.F., Saad S.T.O.;
RT   "Arginine 490 is a hot spot for mutation in the band 3 gene in
RT   hereditary spherocytosis.";
RL   Eur. J. Haematol. 63:360-361(1999).
RN   [59]
RP   VARIANTS DRTA-HA ASP-701 AND VAL-850 DEL, VARIANT AD-DRTA ASP-858,
RP   FUNCTION, SUBCELLULAR LOCATION, AND TISSUE SPECIFICITY.
RX   PubMed=10926824; DOI=10.1042/bj3500041;
RA   Bruce L.J., Wrong O., Toye A.M., Young M.T., Ogle G., Ismail Z.,
RA   Sinha A.K., McMaster P., Hwaihwanje I., Nash G.B., Hart S., Lavu E.,
RA   Palmer R., Othman A., Unwin R.J., Tanner M.J.A.;
RT   "Band 3 mutations, renal tubular acidosis and South-East Asian
RT   ovalocytosis in Malaysia and Papua New Guinea: loss of up to 95% band
RT   3 transport in red cells.";
RL   Biochem. J. 350:41-51(2000).
RN   [60]
RP   VARIANT SPH4 MET-488.
RX   PubMed=10942416;
RA   Ribeiro M.L., Alloisio N., Almeida H., Gomes C., Texier P., Lemos C.,
RA   Mimoso G., Morle L., Bey-Cabet F., Rudigoz R.-C., Delaunay J.,
RA   Tamagnini G.;
RT   "Severe hereditary spherocytosis and distal renal tubular acidosis
RT   associated with the total absence of band 3.";
RL   Blood 96:1602-1604(2000).
RN   [61]
RP   VARIANTS SPH4 ARG-130; ARG-455; ARG-714; TRP-760; GLN-760; HIS-808;
RP   ARG-837 AND MET-837, AND VARIANTS ALA-38; GLU-56; ASP-72 AND LEU-854.
RX   PubMed=10745622;
RA   Yawata Y., Kanzaki A., Yawata A., Doerfler W., Oezcan R., Eber S.W.;
RT   "Characteristic features of the genotype and phenotype of hereditary
RT   spherocytosis in the Japanese population.";
RL   Int. J. Hematol. 71:118-135(2000).
RN   [62]
RP   CHARACTERIZATION OF VARIANTS PRO-707; GLN-760; TRP-760; CYS-808;
RP   PRO-834; MET-837 AND TRP-870.
RX   PubMed=11208088; DOI=10.1034/j.1600-0854.2000.011208.x;
RA   Quilty J.A., Reithmeier R.A.;
RT   "Trafficking and folding defects in hereditary spherocytosis mutants
RT   of the human red cell anion exchanger.";
RL   Traffic 1:987-998(2000).
RN   [63]
RP   VARIANTS BLOOD GROUP NFLD+ ASP-429 AND ALA-561, AND VARIANT BLOOD
RP   GROUP BOW+ SER-561.
RX   PubMed=10738034; DOI=10.1046/j.1537-2995.2000.40030325.x;
RA   McManus K., Pongoski J., Coghlan G., Zelinski T.;
RT   "Amino acid substitutions in human erythroid protein band 3 account
RT   for the low-incidence antigens NFLD and BOW.";
RL   Transfusion 40:325-329(2000).
RN   [64]
RP   VARIANT BLOOD GROUP FR(A+) LYS-480.
RX   PubMed=11061863; DOI=10.1046/j.1537-2995.2000.40101246.x;
RA   McManus K., Lupe K., Coghlan G., Zelinski T.;
RT   "An amino acid substitution in the putative second extracellular loop
RT   of RBC band 3 accounts for the Froese blood group polymorphism.";
RL   Transfusion 40:1246-1249(2000).
RN   [65]
RP   VARIANTS BLOOD GROUP SW(A+) GLN-646 AND TRP-646.
RX   PubMed=11155072; DOI=10.1159/000056733;
RA   Zelinski T., Rusnak A., McManus K., Coghlan G.;
RT   "Distinctive Swann blood group genotypes: molecular investigations.";
RL   Vox Sang. 79:215-218(2000).
RN   [66]
RP   VARIANTS SPH4 LYS-90 AND TRP-870.
RX   PubMed=11380459; DOI=10.1046/j.1365-2141.2001.02800.x;
RA   Bracher N.A., Lyons C.A., Wessels G., Mansvelt E., Coetzer T.L.;
RT   "Band 3 Cape Town (E90K) causes severe hereditary spherocytosis in
RT   combination with band 3 Prague III.";
RL   Br. J. Haematol. 113:689-693(2001).
RN   [67]
RP   VARIANT DRTA-HA PRO-602, AND VARIANT DRTA-NRC PRO-773.
RX   PubMed=15211439; DOI=10.1053/j.ajkd.2004.03.033;
RA   Sritippayawan S., Sumboonnanonda A., Vasuvattakul S., Keskanokwong T.,
RA   Sawasdee N., Paemanee A., Thuwajit P., Wilairat P., Nimmannit S.,
RA   Malasit P., Yenchitsomanus P.T.;
RT   "Novel compound heterozygous SLC4A1 mutations in Thai patients with
RT   autosomal recessive distal renal tubular acidosis.";
RL   Am. J. Kidney Dis. 44:64-70(2004).
RN   [68]
RP   VARIANT AD-DRTA ARG-609, FUNCTION, SUBCELLULAR LOCATION, AND
RP   CHARACTERIZATION OF VARIANT AD-DRTA ARG-609.
RX   PubMed=14734552; DOI=10.1074/jbc.M400188200;
RA   Rungroj N., Devonald M.A.J., Cuthbert A.W., Reimann F.,
RA   Akkarapatumwong V., Yenchitsomanus P.-T., Bennett W.M., Karet F.E.;
RT   "A novel missense mutation in AE1 causing autosomal dominant distal
RT   renal tubular acidosis retains normal transport function but is
RT   mistargeted in polarized epithelial cells.";
RL   J. Biol. Chem. 279:13833-13838(2004).
RN   [69]
RP   VARIANT SPH4 LYS-663.
RX   PubMed=15813913; DOI=10.1111/j.1600-0609.2004.00405.x;
RA   Lima P.R.M., Baratti M.O., Chiattone M.L., Costa F.F., Saad S.T.O.;
RT   "Band 3Tambau: a de novo mutation in the AE1 gene associated with
RT   hereditary spherocytosis. Implications for anion exchange and
RT   insertion into the red blood cell membrane.";
RL   Eur. J. Haematol. 74:396-401(2005).
RN   [70]
RP   INVOLVEMENT IN CHC AND SPH4, VARIANT GLU-56, VARIANTS CHC PRO-687;
RP   PRO-731 AND ARG-734, VARIANTS SPH4 TYR-705 AND GLN-760,
RP   CHARACTERIZATION OF VARIANTS CHC PRO-687; PRO-731 AND ARG-734, AND
RP   CHARACTERIZATION OF VARIANTS SPH4 TYR-705 AND GLN-760.
RX   PubMed=16227998; DOI=10.1038/ng1656;
RA   Bruce L.J., Robinson H.C., Guizouarn H., Borgese F., Harrison P.,
RA   King M.-J., Goede J.S., Coles S.E., Gore D.M., Lutz H.U.,
RA   Ficarella R., Layton D.M., Iolascon A., Ellory J.C., Stewart G.W.;
RT   "Monovalent cation leaks in human red cells caused by single amino-
RT   acid substitutions in the transport domain of the band 3 chloride-
RT   bicarbonate exchanger, AE1.";
RL   Nat. Genet. 37:1258-1263(2005).
RN   [71]
RP   CHARACTERIZATION OF VARIANT DRTA-HA ASP-701, CHARACTERIZATION OF
RP   VARIANT AD-DRTA ASP-858, SUBUNIT, SUBCELLULAR LOCATION, AND FUNCTION.
RX   PubMed=20151848; DOI=10.3109/09687681003588020;
RA   Ungsupravate D., Sawasdee N., Khositseth S., Udomchaiprasertkul W.,
RA   Khoprasert S., Li J., Reithmeier R.A., Yenchitsomanus P.T.;
RT   "Impaired trafficking and intracellular retention of mutant kidney
RT   anion exchanger 1 proteins (G701D and A858D) associated with distal
RT   renal tubular acidosis.";
RL   Mol. Membr. Biol. 27:92-103(2010).
RN   [72]
RP   VARIANT ILE-862.
RX   PubMed=21849667; DOI=10.1152/ajpcell.00054.2011;
RA   Stewart A.K., Shmukler B.E., Vandorpe D.H., Rivera A., Heneghan J.F.,
RA   Li X., Hsu A., Karpatkin M., O'Neill A.F., Bauer D.E., Heeney M.M.,
RA   John K., Kuypers F.A., Gallagher P.G., Lux S.E., Brugnara C.,
RA   Westhoff C.M., Alper S.L.;
RT   "Loss-of-function and gain-of-function phenotypes of stomatocytosis
RT   mutant RhAG F65S.";
RL   Am. J. Physiol. 301:C1325-C1343(2011).
CC   -!- FUNCTION: Functions both as a transporter that mediates
CC       electroneutral anion exchange across the cell membrane and as a
CC       structural protein. Major integral membrane glycoprotein of the
CC       erythrocyte membrane; required for normal flexibility and
CC       stability of the erythrocyte membrane and for normal erythrocyte
CC       shape via the interactions of its cytoplasmic domain with
CC       cytoskeletal proteins, glycolytic enzymes, and hemoglobin.
CC       Functions as a transporter that mediates the 1:1 exchange of
CC       inorganic anions across the erythrocyte membrane. Mediates
CC       chloride-bicarbonate exchange in the kidney, and is required for
CC       normal acidification of the urine. {ECO:0000269|PubMed:10926824,
CC       ECO:0000269|PubMed:14734552, ECO:0000269|PubMed:1538405,
CC       ECO:0000269|PubMed:20151848, ECO:0000269|PubMed:24121512}.
CC   -!- ENZYME REGULATION: Phenyl isothiocyanate inhibits anion transport
CC       in vitro.
CC   -!- SUBUNIT: A dimer in solution, but in its membrane environment, it
CC       exists primarily as a mixture of dimers and tetramers and spans
CC       the membrane asymmetrically. Interacts (via cytoplasmic N-terminal
CC       domain) with ANK1 (via N-terminal ANK repeats); tetramer formation
CC       is critical for ankyrin association. Interacts with STOM. Isoform
CC       2 interacts with TM139 (PubMed:26049106).
CC       {ECO:0000269|PubMed:11049968, ECO:0000269|PubMed:20151848,
CC       ECO:0000269|PubMed:23219802, ECO:0000269|PubMed:26049106,
CC       ECO:0000269|PubMed:7665627}.
CC   -!- INTERACTION:
CC       P05026:ATP1B1; NbExp=8; IntAct=EBI-7576138, EBI-714630;
CC       A5K5E5:PVX_088820 (xeno); NbExp=8; IntAct=EBI-7576138, EBI-11621504;
CC   -!- SUBCELLULAR LOCATION: Cell membrane {ECO:0000269|PubMed:10926824,
CC       ECO:0000269|PubMed:24121512, ECO:0000269|PubMed:26542571,
CC       ECO:0000269|PubMed:7506871}; Multi-pass membrane protein
CC       {ECO:0000269|PubMed:26542571}. Basolateral cell membrane
CC       {ECO:0000269|PubMed:7506871}; Multi-pass membrane protein
CC       {ECO:0000269|PubMed:7506871}. Note=Detected in the erythrocyte
CC       cell membrane and on the basolateral membrane of alpha-
CC       intercalated cells in the collecting duct in the kidney.
CC       {ECO:0000269|PubMed:7506871}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=2;
CC       Name=1; Synonyms=eAE1, Erythrocyte;
CC         IsoId=P02730-1; Sequence=Displayed;
CC       Name=2 {ECO:0000269|PubMed:7506871}; Synonyms=kAE1, Kidney;
CC         IsoId=P02730-2; Sequence=VSP_057833;
CC   -!- TISSUE SPECIFICITY: Detected in erythrocytes (at protein level)
CC       (PubMed:7506871, PubMed:26542571). Isoform 2 is expressed in
CC       kidney (at protein level) (PubMed:7506871).
CC       {ECO:0000269|PubMed:10926824, ECO:0000269|PubMed:1538405,
CC       ECO:0000269|PubMed:23219802, ECO:0000269|PubMed:26542571,
CC       ECO:0000269|PubMed:7506871}.
CC   -!- PTM: Phosphorylated on Tyr-8 and Tyr-21 most likely by SYK. PP1-
CC       resistant phosphorylation that precedes Tyr-359 and Tyr-904
CC       phosphorylation. {ECO:0000269|PubMed:10942405,
CC       ECO:0000269|PubMed:1998697}.
CC   -!- PTM: Phosphorylated on Tyr-359 and Tyr-904 most likely by LYN.
CC       PP1-inhibited phosphorylation that follows Tyr-8 and Tyr-21
CC       phosphorylation. {ECO:0000269|PubMed:10942405,
CC       ECO:0000269|PubMed:1998697}.
CC   -!- PTM: N-glycosylated. {ECO:0000269|PubMed:26542571}.
CC   -!- POLYMORPHISM: SLC4A1 is responsible for the Diego blood group
CC       system. The molecular basis of the Di(a)=Di1/Di(b)/Di2 blood group
CC       antigens is a single variation in position 854; Leu-854
CC       corresponds to Di(a) and Pro-854 to Di(b). The molecular basis of
CC       the Wr(a)=Di3/Wr(b)/Di4 blood group antigens is a single variation
CC       in position 658; Lys-658 corresponds to Wr(a) and Glu-658 to
CC       Wr(b). The blood group antigens Wd(a)=Di5 (Waldner-type) has Met-
CC       557; Rb(a)=Di6 has Leu-548 and WARR=Di7 has Ile-552.
CC   -!- POLYMORPHISM: SLC4A1 is responsible for the Swann blood group
CC       system (SW) [MIM:601550]. Sw(a+) has a Gln or a Trp at position
CC       646 and Sw(a-) has an Arg.
CC   -!- POLYMORPHISM: SLC4A1 is responsible for the Froese blood group
CC       system (FR) [MIM:601551]. FR(a+) has a Lys at position 480 and
CC       FR(a-) has a Glu.
CC   -!- POLYMORPHISM: Genetic variations in SLC4A1 are involved in
CC       resistance to malaria [MIM:611162].
CC   -!- DISEASE: Ovalocytosis, Southeast Asian (SAO) [MIM:166900]: A
CC       hereditary hematologic disorder characterized by ovalocytic
CC       erythrocytes that are rigid and exhibit reduced expression of many
CC       erythrocyte antigens. Clinical manifestations include mild
CC       hemolysis, intermittent jaundice and gallstones. However, the
CC       disorder is most often asymptomatic. {ECO:0000269|PubMed:1538405,
CC       ECO:0000269|PubMed:1722314}. Note=The disease is caused by
CC       mutations affecting the gene represented in this entry.
CC   -!- DISEASE: Spherocytosis 4 (SPH4) [MIM:612653]: Spherocytosis is a
CC       hematologic disorder leading to chronic hemolytic anemia and
CC       characterized by numerous abnormally shaped erythrocytes which are
CC       generally spheroidal. {ECO:0000269|PubMed:10580570,
CC       ECO:0000269|PubMed:10745622, ECO:0000269|PubMed:10942416,
CC       ECO:0000269|PubMed:11380459, ECO:0000269|PubMed:1378323,
CC       ECO:0000269|PubMed:15813913, ECO:0000269|PubMed:16227998,
CC       ECO:0000269|PubMed:7530501, ECO:0000269|PubMed:8547122,
CC       ECO:0000269|PubMed:8640229, ECO:0000269|PubMed:8943874,
CC       ECO:0000269|PubMed:9012689, ECO:0000269|PubMed:9207478,
CC       ECO:0000269|PubMed:9233560, ECO:0000269|PubMed:9973643}. Note=The
CC       disease is caused by mutations affecting the gene represented in
CC       this entry.
CC   -!- DISEASE: Renal tubular acidosis, distal, autosomal dominant (AD-
CC       dRTA) [MIM:179800]: An autosomal dominant disease characterized by
CC       reduced ability to acidify urine, variable hyperchloremic
CC       hypokalemic metabolic acidosis, nephrocalcinosis, and
CC       nephrolithiasis. It is due to functional failure of alpha-
CC       intercalated cells of the cortical collecting duct of the distal
CC       nephron, where vectorial proton transport is required for urinary
CC       acidification. Note=The disease is caused by mutations affecting
CC       the gene represented in this entry.
CC   -!- DISEASE: Renal tubular acidosis, distal, with hemolytic anemia
CC       (dRTA-HA) [MIM:611590]: A disease characterized by the association
CC       of hemolytic anemia with distal renal tubular acidosis, the
CC       reduced ability to acidify urine resulting in variable
CC       hyperchloremic hypokalemic metabolic acidosis, nephrocalcinosis,
CC       and nephrolithiasis. {ECO:0000269|PubMed:10926824,
CC       ECO:0000269|PubMed:15211439, ECO:0000269|PubMed:9854053}. Note=The
CC       disease is caused by mutations affecting the gene represented in
CC       this entry.
CC   -!- DISEASE: Renal tubular acidosis, distal, with normal red cell
CC       morphology (dRTA-NRC) [MIM:611590]: A disease characterized by
CC       reduced ability to acidify urine, variable hyperchloremic
CC       hypokalemic metabolic acidosis, nephrocalcinosis, and
CC       nephrolithiasis. It is due to functional failure of alpha-
CC       intercalated cells of the cortical collecting duct of the distal
CC       nephron, where vectorial proton transport is required for urinary
CC       acidification. {ECO:0000269|PubMed:15211439}. Note=The disease is
CC       caused by mutations affecting the gene represented in this entry.
CC   -!- DISEASE: Cryohydrocytosis (CHC) [MIM:185020]: An autosomal
CC       dominant disorder of red cell membrane permeability characterized
CC       by cold-induced changes in cell volume, resulting in cold-
CC       sensitive stomatocytosis, and increased erythrocyte osmotic
CC       fragility and autohemolysis at 4 degrees Celsius. Patients present
CC       with mild to moderate hemolytic anemia, splenomegaly, fatigue, and
CC       pseudohyperkalemia due to a potassium leak from the erythrocytes.
CC       {ECO:0000269|PubMed:16227998}. Note=The disease is caused by
CC       mutations affecting distinct genetic loci, including the gene
CC       represented in this entry.
CC   -!- SIMILARITY: Belongs to the anion exchanger (TC 2.A.31) family.
CC       {ECO:0000305}.
CC   -!- WEB RESOURCE: Name=Wikipedia; Note=Band 3 entry;
CC       URL="https://en.wikipedia.org/wiki/Band_3";
CC   -!- WEB RESOURCE: Name=dbRBC/BGMUT; Note=Blood group antigen gene
CC       mutation database;
CC       URL="https://www.ncbi.nlm.nih.gov/gv/mhc/xslcgi.cgi?cmd=bgmut/systems_info&system=diego";
CC   -!- WEB RESOURCE: Name=SeattleSNPs;
CC       URL="http://pga.gs.washington.edu/data/slc4a1/";
CC   -!- WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncology
CC       and Haematology;
CC       URL="http://atlasgeneticsoncology.org/Genes/SLC4A1ID42325ch17q21.html";
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; X12609; CAA31128.1; -; mRNA.
DR   EMBL; M27819; AAA35514.1; -; mRNA.
DR   EMBL; DQ419529; ABD74692.1; -; mRNA.
DR   EMBL; GQ981383; ADN39420.1; -; mRNA.
DR   EMBL; GQ981384; ADN39421.1; -; mRNA.
DR   EMBL; DQ072115; AAY57324.1; -; Genomic_DNA.
DR   EMBL; CH471178; EAW51614.1; -; Genomic_DNA.
DR   EMBL; BC096106; AAH96106.1; -; mRNA.
DR   EMBL; BC096107; AAH96107.1; -; mRNA.
DR   EMBL; BC099628; AAH99628.1; -; mRNA.
DR   EMBL; BC099629; AAH99629.1; -; mRNA.
DR   EMBL; BC101570; AAI01571.1; -; mRNA.
DR   EMBL; BC101574; AAI01575.1; -; mRNA.
DR   EMBL; S68680; AAC60608.2; -; mRNA.
DR   CCDS; CCDS11481.1; -. [P02730-1]
DR   PIR; A36218; B3HU.
DR   RefSeq; NP_000333.1; NM_000342.3. [P02730-1]
DR   RefSeq; XP_005257650.1; XM_005257593.4. [P02730-2]
DR   UniGene; Hs.210751; -.
DR   UniGene; Hs.443948; -.
DR   PDB; 1BH7; NMR; -; A=803-835.
DR   PDB; 1BNX; NMR; -; A=389-430.
DR   PDB; 1BTQ; NMR; -; A=405-424.
DR   PDB; 1BTR; NMR; -; A=405-424.
DR   PDB; 1BTS; NMR; -; A=436-456.
DR   PDB; 1BTT; NMR; -; A=436-456.
DR   PDB; 1BZK; NMR; -; A=389-430.
DR   PDB; 1HYN; X-ray; 2.60 A; P/Q/R/S=1-379.
DR   PDB; 2BTA; NMR; -; A=1-15.
DR   PDB; 2BTB; NMR; -; A=1-15.
DR   PDB; 3BTB; NMR; -; A=1-15.
DR   PDB; 4KY9; X-ray; 2.23 A; A/P=51-356.
DR   PDB; 4YZF; X-ray; 3.50 A; A/B/C/D=1-911.
DR   PDBsum; 1BH7; -.
DR   PDBsum; 1BNX; -.
DR   PDBsum; 1BTQ; -.
DR   PDBsum; 1BTR; -.
DR   PDBsum; 1BTS; -.
DR   PDBsum; 1BTT; -.
DR   PDBsum; 1BZK; -.
DR   PDBsum; 1HYN; -.
DR   PDBsum; 2BTA; -.
DR   PDBsum; 2BTB; -.
DR   PDBsum; 3BTB; -.
DR   PDBsum; 4KY9; -.
DR   PDBsum; 4YZF; -.
DR   ProteinModelPortal; P02730; -.
DR   SMR; P02730; -.
DR   BioGrid; 112412; 11.
DR   DIP; DIP-42428N; -.
DR   IntAct; P02730; 9.
DR   MINT; MINT-1344291; -.
DR   STRING; 9606.ENSP00000262418; -.
DR   MoonProt; P02730; -.
DR   TCDB; 2.A.31.1.1; the anion exchanger (ae) family.
DR   iPTMnet; P02730; -.
DR   PhosphoSitePlus; P02730; -.
DR   SwissPalm; P02730; -.
DR   BioMuta; SLC4A1; -.
DR   DMDM; 114787; -.
DR   EPD; P02730; -.
DR   PaxDb; P02730; -.
DR   PeptideAtlas; P02730; -.
DR   PRIDE; P02730; -.
DR   Ensembl; ENST00000262418; ENSP00000262418; ENSG00000004939. [P02730-1]
DR   GeneID; 6521; -.
DR   KEGG; hsa:6521; -.
DR   UCSC; uc002igf.5; human. [P02730-1]
DR   CTD; 6521; -.
DR   DisGeNET; 6521; -.
DR   GeneCards; SLC4A1; -.
DR   HGNC; HGNC:11027; SLC4A1.
DR   HPA; CAB034438; -.
DR   HPA; HPA015584; -.
DR   HPA; HPA063911; -.
DR   MalaCards; SLC4A1; -.
DR   MIM; 109270; gene+phenotype.
DR   MIM; 110500; phenotype.
DR   MIM; 112010; phenotype.
DR   MIM; 112050; phenotype.
DR   MIM; 130600; phenotype.
DR   MIM; 166900; phenotype.
DR   MIM; 179800; phenotype.
DR   MIM; 185020; phenotype.
DR   MIM; 601550; phenotype.
DR   MIM; 601551; phenotype.
DR   MIM; 611162; phenotype.
DR   MIM; 611590; phenotype.
DR   MIM; 612653; phenotype.
DR   neXtProt; NX_P02730; -.
DR   OpenTargets; ENSG00000004939; -.
DR   Orphanet; 93608; Autosomal dominant distal renal tubular acidosis.
DR   Orphanet; 93610; Distal renal tubular acidosis with anemia.
DR   Orphanet; 398088; Hereditary cryohydrocytosis with normal stomatin.
DR   Orphanet; 822; Hereditary spherocytosis.
DR   Orphanet; 98868; Southeast Asian ovalocytosis.
DR   PharmGKB; PA35895; -.
DR   eggNOG; KOG1172; Eukaryota.
DR   eggNOG; ENOG410XPHD; LUCA.
DR   GeneTree; ENSGT00760000119021; -.
DR   HOVERGEN; HBG004326; -.
DR   InParanoid; P02730; -.
DR   KO; K06573; -.
DR   OMA; FKPPKYH; -.
DR   OrthoDB; EOG091G01FT; -.
DR   PhylomeDB; P02730; -.
DR   TreeFam; TF313630; -.
DR   Reactome; R-HSA-1237044; Erythrocytes take up carbon dioxide and release oxygen.
DR   Reactome; R-HSA-1247673; Erythrocytes take up oxygen and release carbon dioxide.
DR   Reactome; R-HSA-425381; Bicarbonate transporters.
DR   SIGNOR; P02730; -.
DR   ChiTaRS; SLC4A1; human.
DR   EvolutionaryTrace; P02730; -.
DR   GeneWiki; Band_3; -.
DR   GenomeRNAi; 6521; -.
DR   PMAP-CutDB; P02730; -.
DR   PRO; PR:P02730; -.
DR   Proteomes; UP000005640; Chromosome 17.
DR   Bgee; ENSG00000004939; -.
DR   ExpressionAtlas; P02730; baseline and differential.
DR   Genevisible; P02730; HS.
DR   GO; GO:0016323; C:basolateral plasma membrane; IDA:UniProtKB.
DR   GO; GO:0072562; C:blood microparticle; IDA:UniProtKB.
DR   GO; GO:0030863; C:cortical cytoskeleton; IDA:UniProtKB.
DR   GO; GO:0070062; C:extracellular exosome; IDA:UniProtKB.
DR   GO; GO:0016021; C:integral component of membrane; NAS:UniProtKB.
DR   GO; GO:0005887; C:integral component of plasma membrane; IDA:UniProtKB.
DR   GO; GO:0005886; C:plasma membrane; TAS:Reactome.
DR   GO; GO:0030018; C:Z disc; ISS:UniProtKB.
DR   GO; GO:0008509; F:anion transmembrane transporter activity; TAS:ProtInc.
DR   GO; GO:0015301; F:anion:anion antiporter activity; IDA:UniProtKB.
DR   GO; GO:0030506; F:ankyrin binding; IPI:BHF-UCL.
DR   GO; GO:0015106; F:bicarbonate transmembrane transporter activity; IDA:UniProtKB.
DR   GO; GO:0015108; F:chloride transmembrane transporter activity; ISS:UniProtKB.
DR   GO; GO:0005452; F:inorganic anion exchanger activity; IDA:UniProtKB.
DR   GO; GO:0043495; F:protein anchor; TAS:BHF-UCL.
DR   GO; GO:0042803; F:protein homodimerization activity; IPI:BHF-UCL.
DR   GO; GO:0006820; P:anion transport; IDA:UniProtKB.
DR   GO; GO:0015701; P:bicarbonate transport; IDA:UniProtKB.
DR   GO; GO:0006873; P:cellular ion homeostasis; TAS:ProtInc.
DR   GO; GO:0006821; P:chloride transport; ISS:UniProtKB.
DR   GO; GO:0051453; P:regulation of intracellular pH; IBA:GO_Central.
DR   Gene3D; 3.40.930.10; -; 1.
DR   InterPro; IPR001717; Anion_exchange.
DR   InterPro; IPR002977; Anion_exchange_1.
DR   InterPro; IPR018241; Anion_exchange_CS.
DR   InterPro; IPR013769; Band3_cytoplasmic_dom.
DR   InterPro; IPR011531; HCO3_transpt_C.
DR   InterPro; IPR003020; HCO3_transpt_euk.
DR   InterPro; IPR016152; PTrfase/Anion_transptr.
DR   PANTHER; PTHR11453; PTHR11453; 1.
DR   Pfam; PF07565; Band_3_cyto; 1.
DR   Pfam; PF00955; HCO3_cotransp; 2.
DR   PRINTS; PR00165; ANIONEXCHNGR.
DR   PRINTS; PR01187; ANIONEXHNGR1.
DR   PRINTS; PR01231; HCO3TRNSPORT.
DR   SUPFAM; SSF55804; SSF55804; 1.
DR   TIGRFAMs; TIGR00834; ae; 1.
DR   PROSITE; PS00219; ANION_EXCHANGER_1; 1.
DR   PROSITE; PS00220; ANION_EXCHANGER_2; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Acetylation; Alternative splicing; Anion exchange;
KW   Blood group antigen; Cell membrane; Complete proteome;
KW   Direct protein sequencing; Disease mutation; Elliptocytosis;
KW   Glycoprotein; Hereditary hemolytic anemia; Ion transport; Lipoprotein;
KW   Membrane; Palmitate; Phosphoprotein; Polymorphism; Reference proteome;
KW   Transmembrane; Transmembrane helix; Transport.
FT   CHAIN         1    911       Band 3 anion transport protein.
FT                                /FTId=PRO_0000079209.
FT   TOPO_DOM      1    403       Cytoplasmic.
FT                                {ECO:0000269|PubMed:26542571}.
FT   TRANSMEM    404    427       Helical; Name=1.
FT                                {ECO:0000269|PubMed:26542571}.
FT   TOPO_DOM    428    435       Extracellular.
FT                                {ECO:0000269|PubMed:26542571}.
FT   TRANSMEM    436    456       Helical; Name=2.
FT                                {ECO:0000269|PubMed:26542571}.
FT   TOPO_DOM    457    459       Cytoplasmic.
FT                                {ECO:0000269|PubMed:26542571}.
FT   TRANSMEM    460    476       Discontinuously helical; Name=3.
FT                                {ECO:0000269|PubMed:26542571}.
FT   TOPO_DOM    477    485       Extracellular.
FT                                {ECO:0000269|PubMed:26542571}.
FT   TRANSMEM    486    506       Helical; Name=4.
FT                                {ECO:0000269|PubMed:26542571}.
FT   TOPO_DOM    507    518       Cytoplasmic.
FT                                {ECO:0000269|PubMed:26542571}.
FT   TRANSMEM    519    541       Helical; Name=5.
FT                                {ECO:0000269|PubMed:26542571}.
FT   TOPO_DOM    542    570       Extracellular.
FT                                {ECO:0000269|PubMed:26542571}.
FT   TRANSMEM    571    591       Helical; Name=6.
FT                                {ECO:0000269|PubMed:26542571}.
FT   TOPO_DOM    592    602       Cytoplasmic.
FT                                {ECO:0000269|PubMed:26542571}.
FT   TRANSMEM    603    623       Helical; Name=7.
FT                                {ECO:0000269|PubMed:26542571}.
FT   TOPO_DOM    624    663       Extracellular.
FT                                {ECO:0000269|PubMed:26542571}.
FT   TRANSMEM    664    684       Helical; Name=8.
FT                                {ECO:0000269|PubMed:26542571}.
FT   TOPO_DOM    685    700       Cytoplasmic.
FT                                {ECO:0000269|PubMed:26542571}.
FT   TRANSMEM    701    719       Helical; Name=9.
FT                                {ECO:0000269|PubMed:26542571}.
FT   TRANSMEM    720    737       Discontinuously helical; Name=10.
FT                                {ECO:0000269|PubMed:26542571}.
FT   TOPO_DOM    738    760       Cytoplasmic.
FT                                {ECO:0000269|PubMed:26542571}.
FT   TRANSMEM    761    781       Helical; Name=11.
FT                                {ECO:0000269|PubMed:26542571}.
FT   TRANSMEM    782    800       Helical; Name=12.
FT                                {ECO:0000269|PubMed:26542571}.
FT   TOPO_DOM    801    838       Cytoplasmic.
FT                                {ECO:0000269|PubMed:26542571}.
FT   INTRAMEM    839    869       Discontinuously helical.
FT                                {ECO:0000269|PubMed:26542571}.
FT   TOPO_DOM    870    911       Cytoplasmic.
FT                                {ECO:0000269|PubMed:26542571}.
FT   REGION       55    290       Globular.
FT   REGION      176    185       Interaction with ANK1. {ECO:0000305}.
FT   REGION      304    357       Dimerization arm.
FT   REGION      559    630       Involved in anion transport.
FT   SITE        590    590       Important for anion transport.
FT   SITE        681    681       Important for anion-proton cotransport.
FT   MOD_RES       1      1       N-acetylmethionine.
FT                                {ECO:0000269|PubMed:2790053,
FT                                ECO:0000269|PubMed:701248}.
FT   MOD_RES       8      8       Phosphotyrosine.
FT                                {ECO:0000269|PubMed:10942405,
FT                                ECO:0000269|PubMed:1998697}.
FT   MOD_RES      21     21       Phosphotyrosine.
FT                                {ECO:0000269|PubMed:10942405,
FT                                ECO:0000269|PubMed:1998697}.
FT   MOD_RES      46     46       Phosphotyrosine.
FT                                {ECO:0000269|PubMed:1998697}.
FT   MOD_RES     185    185       Phosphoserine.
FT                                {ECO:0000250|UniProtKB:P23562}.
FT   MOD_RES     350    350       Phosphoserine.
FT                                {ECO:0000250|UniProtKB:P04919}.
FT   MOD_RES     359    359       Phosphotyrosine.
FT                                {ECO:0000269|PubMed:10942405}.
FT   MOD_RES     904    904       Phosphotyrosine.
FT                                {ECO:0000269|PubMed:10942405}.
FT   LIPID       843    843       S-palmitoyl cysteine.
FT                                {ECO:0000269|PubMed:1885574}.
FT   CARBOHYD    642    642       N-linked (GlcNAc...) (complex)
FT                                asparagine. {ECO:0000269|PubMed:10861210,
FT                                ECO:0000269|PubMed:24121512}.
FT   VAR_SEQ       1     65       Missing (in isoform 2).
FT                                {ECO:0000269|PubMed:7506871}.
FT                                /FTId=VSP_057833.
FT   VARIANT      27     27       P -> H (in dbSNP:rs55777403).
FT                                {ECO:0000269|PubMed:15489334}.
FT                                /FTId=VAR_058035.
FT   VARIANT      38     38       D -> A (in dbSNP:rs5035).
FT                                {ECO:0000269|PubMed:10745622,
FT                                ECO:0000269|PubMed:16252102,
FT                                ECO:0000269|PubMed:9012689,
FT                                ECO:0000269|Ref.5}.
FT                                /FTId=VAR_014612.
FT   VARIANT      40     40       E -> K (found in patients with hemolytic
FT                                anemia; unknown pathological
FT                                significance; Montefiore;
FT                                dbSNP:rs45562031).
FT                                {ECO:0000269|PubMed:8471774,
FT                                ECO:0000269|PubMed:8640229}.
FT                                /FTId=VAR_000798.
FT   VARIANT      45     45       D -> E (in dbSNP:rs34700496).
FT                                /FTId=VAR_036693.
FT   VARIANT      56     56       K -> E (in Di(a)/Memphis-II antigen;
FT                                dbSNP:rs5036).
FT                                {ECO:0000269|PubMed:10745622,
FT                                ECO:0000269|PubMed:16227998,
FT                                ECO:0000269|PubMed:1678289,
FT                                ECO:0000269|PubMed:1722314,
FT                                ECO:0000269|PubMed:8206915,
FT                                ECO:0000269|Ref.5}.
FT                                /FTId=VAR_000799.
FT   VARIANT      68     68       E -> K (in dbSNP:rs13306787).
FT                                /FTId=VAR_039290.
FT   VARIANT      72     72       E -> D (in dbSNP:rs13306788).
FT                                {ECO:0000269|PubMed:10745622}.
FT                                /FTId=VAR_058036.
FT   VARIANT      73     73       L -> M (in dbSNP:rs781490287).
FT                                {ECO:0000269|PubMed:9012689}.
FT                                /FTId=VAR_039291.
FT   VARIANT      90     90       E -> K (in SPH4; Cape Town;
FT                                dbSNP:rs28929480).
FT                                {ECO:0000269|PubMed:11380459}.
FT                                /FTId=VAR_013784.
FT   VARIANT     112    112       R -> S (in dbSNP:rs5037).
FT                                /FTId=VAR_014613.
FT   VARIANT     130    130       G -> R (in SPH4; Fukoka;
FT                                dbSNP:rs121912749).
FT                                {ECO:0000269|PubMed:10745622}.
FT                                /FTId=VAR_013785.
FT   VARIANT     147    147       P -> S (in SPH4; Mondego).
FT                                {ECO:0000269|PubMed:9207478}.
FT                                /FTId=VAR_013786.
FT   VARIANT     285    285       A -> D (in SPH4; Boston).
FT                                {ECO:0000269|PubMed:8943874}.
FT                                /FTId=VAR_013787.
FT   VARIANT     327    327       P -> R (in SPH4; Tuscaloosa;
FT                                dbSNP:rs28931583).
FT                                {ECO:0000269|PubMed:1378323}.
FT                                /FTId=VAR_000800.
FT   VARIANT     400    408       Missing (in SAO; increased rigidity of
FT                                the erythrocyte membrane leading to
FT                                increased resistance to shear stress and
FT                                increased resistance to P.falciparum).
FT                                {ECO:0000269|PubMed:1538405,
FT                                ECO:0000269|PubMed:1722314}.
FT                                /FTId=VAR_000801.
FT   VARIANT     429    429       E -> D (in NFLD+ antigen).
FT                                {ECO:0000269|PubMed:10738034}.
FT                                /FTId=VAR_058037.
FT   VARIANT     432    432       R -> W (in ELO antigen;
FT                                dbSNP:rs373768879).
FT                                /FTId=VAR_013788.
FT   VARIANT     442    442       I -> F (in dbSNP:rs5018).
FT                                /FTId=VAR_014614.
FT   VARIANT     455    455       G -> E (in SPH4; Benesov).
FT                                {ECO:0000269|PubMed:8943874}.
FT                                /FTId=VAR_013789.
FT   VARIANT     455    455       G -> R (in SPH4; Yamagata).
FT                                {ECO:0000269|PubMed:10745622}.
FT                                /FTId=VAR_058038.
FT   VARIANT     480    480       E -> K (in FR(a+) antigen;
FT                                dbSNP:rs121912756).
FT                                {ECO:0000269|PubMed:11061863}.
FT                                /FTId=VAR_013790.
FT   VARIANT     488    488       V -> M (in SPH4; Coimbra; also in AR-
FT                                dRTA; dbSNP:rs28931584).
FT                                {ECO:0000269|PubMed:10942416,
FT                                ECO:0000269|PubMed:9207478}.
FT                                /FTId=VAR_013791.
FT   VARIANT     490    490       R -> C (in SPH4; Bicetre I).
FT                                {ECO:0000269|PubMed:9233560}.
FT                                /FTId=VAR_013792.
FT   VARIANT     490    490       R -> H (in SPH4; Pinhal).
FT                                {ECO:0000269|PubMed:10580570}.
FT                                /FTId=VAR_058039.
FT   VARIANT     508    508       E -> K (in dbSNP:rs45568837).
FT                                {ECO:0000269|Ref.5}.
FT                                /FTId=VAR_025090.
FT   VARIANT     518    518       R -> C (in SPH4; Dresden;
FT                                dbSNP:rs868742796).
FT                                {ECO:0000269|PubMed:8640229}.
FT                                /FTId=VAR_000802.
FT   VARIANT     548    548       P -> L (in RB(A) antigen).
FT                                /FTId=VAR_000803.
FT   VARIANT     551    551       K -> N (in TR(A) antigen).
FT                                /FTId=VAR_013793.
FT   VARIANT     552    552       T -> I (in WARR antigen).
FT                                /FTId=VAR_000804.
FT   VARIANT     555    555       Y -> H (in VG(a) antigen).
FT                                /FTId=VAR_013794.
FT   VARIANT     557    557       V -> M (in WD(a) antigen;
FT                                dbSNP:rs121912743).
FT                                /FTId=VAR_000805.
FT   VARIANT     561    561       P -> A (in NFLD+ antigen).
FT                                {ECO:0000269|PubMed:10738034}.
FT                                /FTId=VAR_058040.
FT   VARIANT     561    561       P -> S (in BOW antigen).
FT                                {ECO:0000269|PubMed:10738034}.
FT                                /FTId=VAR_013795.
FT   VARIANT     565    565       G -> A (in WU antigen;
FT                                dbSNP:rs551784583).
FT                                /FTId=VAR_013796.
FT   VARIANT     566    566       P -> A (in KREP antigen).
FT                                /FTId=VAR_013797.
FT   VARIANT     566    566       P -> S (in PN(a) antigen).
FT                                /FTId=VAR_013798.
FT   VARIANT     569    569       N -> K (in BP(a) antigen).
FT                                /FTId=VAR_013799.
FT   VARIANT     586    586       M -> L (in dbSNP:rs5019).
FT                                /FTId=VAR_014615.
FT   VARIANT     589    589       R -> C (in AD-dRTA; reduced red cell
FT                                sulfate transport and altered
FT                                glycosylation of the red cell band 3 N-
FT                                glycan chain; dbSNP:rs121912745).
FT                                {ECO:0000269|PubMed:9312167}.
FT                                /FTId=VAR_015104.
FT   VARIANT     589    589       R -> H (in AD-dRTA; dbSNP:rs121912744).
FT                                {ECO:0000269|PubMed:9312167,
FT                                ECO:0000269|PubMed:9600966}.
FT                                /FTId=VAR_015105.
FT   VARIANT     589    589       R -> S (in AD-dRTA; dbSNP:rs121912745).
FT                                {ECO:0000269|PubMed:9600966}.
FT                                /FTId=VAR_015106.
FT   VARIANT     602    602       R -> P (in dRTA-HA; dbSNP:rs121912754).
FT                                {ECO:0000269|PubMed:15211439}.
FT                                /FTId=VAR_039292.
FT   VARIANT     609    609       G -> R (in AD-dRTA; detected subapically
FT                                and at the apical membrane as well as at
FT                                the basolateral membrane in contrast to
FT                                the normal basolateral appearance of
FT                                wild-type protein).
FT                                {ECO:0000269|PubMed:14734552}.
FT                                /FTId=VAR_058041.
FT   VARIANT     613    613       S -> F (in AD-dRTA; markedly increased
FT                                red cell sulfate transport but almost
FT                                normal red cell iodide transport;
FT                                dbSNP:rs121912746).
FT                                {ECO:0000269|PubMed:9312167}.
FT                                /FTId=VAR_015107.
FT   VARIANT     646    646       R -> Q (in SW(a+) antigen;
FT                                dbSNP:rs121912757).
FT                                {ECO:0000269|PubMed:11155072}.
FT                                /FTId=VAR_013800.
FT   VARIANT     646    646       R -> W (in SW(a+) antigen;
FT                                dbSNP:rs121912758).
FT                                {ECO:0000269|PubMed:11155072}.
FT                                /FTId=VAR_013801.
FT   VARIANT     656    656       R -> C (in HG(a) antigen;
FT                                dbSNP:rs372514760).
FT                                /FTId=VAR_013802.
FT   VARIANT     656    656       R -> H (in MO(a) antigen;
FT                                dbSNP:rs758868427).
FT                                /FTId=VAR_013803.
FT   VARIANT     658    658       E -> K (in WR(a) antigen;
FT                                dbSNP:rs75731670).
FT                                {ECO:0000269|PubMed:7812009}.
FT                                /FTId=VAR_000806.
FT   VARIANT     663    663       M -> K (in SPH4; Tambau).
FT                                {ECO:0000269|PubMed:15813913}.
FT                                /FTId=VAR_058042.
FT   VARIANT     663    663       Missing (in SPH4; Osnabruck II).
FT                                {ECO:0000269|PubMed:8640229}.
FT                                /FTId=VAR_000807.
FT   VARIANT     687    687       L -> P (in CHC; Blackburn; induces
FT                                abnormal cations sodium and potassium
FT                                fluxes; decreases anion chloride
FT                                transport; dbSNP:rs863225463).
FT                                {ECO:0000269|PubMed:16227998}.
FT                                /FTId=VAR_039293.
FT   VARIANT     688    688       I -> V (in dbSNP:rs5022).
FT                                /FTId=VAR_014616.
FT   VARIANT     690    690       S -> G (in dbSNP:rs5023).
FT                                /FTId=VAR_014617.
FT   VARIANT     701    701       G -> D (in dRTA-HA; impairs expression at
FT                                the cell membrane; dbSNP:rs121912748).
FT                                {ECO:0000269|PubMed:10926824,
FT                                ECO:0000269|PubMed:20151848,
FT                                ECO:0000269|PubMed:9854053}.
FT                                /FTId=VAR_015171.
FT   VARIANT     705    705       D -> Y (in SPH4; Horam; induces abnormal
FT                                cations sodium and potassium fluxes;
FT                                decreases anion chloride transport).
FT                                {ECO:0000269|PubMed:16227998}.
FT                                /FTId=VAR_039294.
FT   VARIANT     707    707       L -> P (in SPH4; Most).
FT                                {ECO:0000269|PubMed:11208088,
FT                                ECO:0000269|PubMed:8943874}.
FT                                /FTId=VAR_013804.
FT   VARIANT     714    714       G -> R (in SPH4; Okinawa).
FT                                {ECO:0000269|PubMed:10745622}.
FT                                /FTId=VAR_013805.
FT   VARIANT     731    731       S -> P (in CHC; Hemel; induces abnormal
FT                                cations sodium and potassium fluxes;
FT                                decreases anion chloride transport;
FT                                dbSNP:rs863225461).
FT                                {ECO:0000269|PubMed:16227998}.
FT                                /FTId=VAR_039295.
FT   VARIANT     734    734       H -> R (in CHC; Hurstpierpont; induces
FT                                abnormal cations sodium and potassium
FT                                fluxes; decreases anion chloride
FT                                transport; dbSNP:rs863225462).
FT                                {ECO:0000269|PubMed:16227998}.
FT                                /FTId=VAR_039296.
FT   VARIANT     760    760       R -> Q (in SPH4; Prague II; induces
FT                                abnormal cations sodium and potassium
FT                                fluxes; decreases anion chloride
FT                                transport; dbSNP:rs121912755).
FT                                {ECO:0000269|PubMed:10745622,
FT                                ECO:0000269|PubMed:11208088,
FT                                ECO:0000269|PubMed:16227998,
FT                                ECO:0000269|PubMed:7530501}.
FT                                /FTId=VAR_013806.
FT   VARIANT     760    760       R -> W (in SPH4; Hradec Kralove;
FT                                dbSNP:rs373916826).
FT                                {ECO:0000269|PubMed:10745622,
FT                                ECO:0000269|PubMed:11208088,
FT                                ECO:0000269|PubMed:7530501}.
FT                                /FTId=VAR_013807.
FT   VARIANT     771    771       G -> D (in SPH4; Chur;
FT                                dbSNP:rs121912741).
FT                                {ECO:0000269|PubMed:8547122}.
FT                                /FTId=VAR_013808.
FT   VARIANT     773    773       S -> P (in dRTA-NRC; dbSNP:rs121912753).
FT                                {ECO:0000269|PubMed:15211439}.
FT                                /FTId=VAR_039297.
FT   VARIANT     783    783       I -> N (in SPH4; Napoli II).
FT                                {ECO:0000269|PubMed:9012689}.
FT                                /FTId=VAR_013809.
FT   VARIANT     808    808       R -> C (in SPH4; Jablonec).
FT                                {ECO:0000269|PubMed:11208088,
FT                                ECO:0000269|PubMed:7530501}.
FT                                /FTId=VAR_013810.
FT   VARIANT     808    808       R -> H (in SPH4; Nara;
FT                                dbSNP:rs866727908).
FT                                {ECO:0000269|PubMed:10745622}.
FT                                /FTId=VAR_013811.
FT   VARIANT     832    832       R -> H (in dbSNP:rs5025).
FT                                /FTId=VAR_014618.
FT   VARIANT     834    834       H -> P (in SPH4; Birmingham).
FT                                {ECO:0000269|PubMed:11208088,
FT                                ECO:0000269|PubMed:8943874}.
FT                                /FTId=VAR_013812.
FT   VARIANT     837    837       T -> A (in SPH4; Tokyo;
FT                                dbSNP:rs121912750).
FT                                {ECO:0000269|PubMed:9973643}.
FT                                /FTId=VAR_013813.
FT   VARIANT     837    837       T -> M (in SPH4; Philadelphia).
FT                                {ECO:0000269|PubMed:10745622,
FT                                ECO:0000269|PubMed:11208088,
FT                                ECO:0000269|PubMed:8943874,
FT                                ECO:0000269|PubMed:9233560}.
FT                                /FTId=VAR_013814.
FT   VARIANT     837    837       T -> R (in SPH4; Nagoya).
FT                                {ECO:0000269|PubMed:10745622}.
FT                                /FTId=VAR_058043.
FT   VARIANT     850    850       Missing (in dRTA-HA).
FT                                {ECO:0000269|PubMed:10926824}.
FT                                /FTId=VAR_015109.
FT   VARIANT     854    854       P -> L (in Di(a)/Memphis-II antigen;
FT                                dbSNP:rs2285644).
FT                                {ECO:0000269|PubMed:10745622,
FT                                ECO:0000269|PubMed:8206915}.
FT                                /FTId=VAR_000808.
FT   VARIANT     858    858       A -> D (in AD-dRTA; impairs expression at
FT                                the cell membrane; dbSNP:rs121912751).
FT                                {ECO:0000269|PubMed:10926824,
FT                                ECO:0000269|PubMed:20151848}.
FT                                /FTId=VAR_015108.
FT   VARIANT     862    862       V -> I (polymorphism; dbSNP:rs5026).
FT                                {ECO:0000269|PubMed:21849667,
FT                                ECO:0000269|Ref.5}.
FT                                /FTId=VAR_014619.
FT   VARIANT     868    868       P -> L (in acanthocytosis; slightly
FT                                increases transporter activity; impairs
FT                                expression at the cell membrane;
FT                                dbSNP:rs121912759).
FT                                {ECO:0000269|PubMed:24121512,
FT                                ECO:0000269|PubMed:8343110}.
FT                                /FTId=VAR_013815.
FT   VARIANT     870    870       R -> W (in SPH4; Prague III;
FT                                dbSNP:rs28931585).
FT                                {ECO:0000269|PubMed:11208088,
FT                                ECO:0000269|PubMed:11380459,
FT                                ECO:0000269|PubMed:7530501}.
FT                                /FTId=VAR_013816.
FT   MUTAGEN      85     85       E->A,R: Impairs expression at the cell
FT                                membrane. {ECO:0000269|PubMed:24121512}.
FT   MUTAGEN     283    283       R->A,E,S: Impairs expression at the cell
FT                                membrane. {ECO:0000269|PubMed:24121512}.
FT   MUTAGEN     642    642       N->D: Loss of N-glycosylation site.
FT                                {ECO:0000269|PubMed:24121512}.
FT   MUTAGEN     681    681       E->Q: Impairs expression at the cell
FT                                membrane. {ECO:0000269|PubMed:24121512}.
FT   CONFLICT     11     11       M -> D (in Ref. 9; AA sequence).
FT                                {ECO:0000305}.
FT   CONFLICT     68     68       E -> EE (in Ref. 9; AA sequence).
FT                                {ECO:0000305}.
FT   CONFLICT    759    759       Q -> H (in Ref. 3; ABD74692).
FT                                {ECO:0000305}.
FT   STRAND        9     12       {ECO:0000244|PDB:2BTA}.
FT   STRAND       58     66       {ECO:0000244|PDB:4KY9}.
FT   STRAND       68     70       {ECO:0000244|PDB:4KY9}.
FT   STRAND       73     88       {ECO:0000244|PDB:4KY9}.
FT   STRAND       90     92       {ECO:0000244|PDB:4KY9}.
FT   HELIX       104    115       {ECO:0000244|PDB:4KY9}.
FT   STRAND      118    123       {ECO:0000244|PDB:4KY9}.
FT   HELIX       128    141       {ECO:0000244|PDB:4KY9}.
FT   HELIX       147    149       {ECO:0000244|PDB:4KY9}.
FT   HELIX       150    157       {ECO:0000244|PDB:4KY9}.
FT   HELIX       164    169       {ECO:0000244|PDB:4KY9}.
FT   STRAND      173    175       {ECO:0000244|PDB:1HYN}.
FT   STRAND      188    190       {ECO:0000244|PDB:4KY9}.
FT   HELIX       195    200       {ECO:0000244|PDB:4KY9}.
FT   HELIX       212    219       {ECO:0000244|PDB:1HYN}.
FT   STRAND      226    234       {ECO:0000244|PDB:4KY9}.
FT   STRAND      241    251       {ECO:0000244|PDB:4KY9}.
FT   STRAND      256    258       {ECO:0000244|PDB:1HYN}.
FT   STRAND      262    270       {ECO:0000244|PDB:4KY9}.
FT   HELIX       278    290       {ECO:0000244|PDB:4KY9}.
FT   HELIX       292    300       {ECO:0000244|PDB:4KY9}.
FT   HELIX       304    316       {ECO:0000244|PDB:4KY9}.
FT   STRAND      319    321       {ECO:0000244|PDB:4KY9}.
FT   HELIX       329    332       {ECO:0000244|PDB:4KY9}.
FT   HELIX       333    335       {ECO:0000244|PDB:4KY9}.
FT   HELIX       336    347       {ECO:0000244|PDB:4KY9}.
FT   STRAND      349    351       {ECO:0000244|PDB:1HYN}.
FT   HELIX       383    393       {ECO:0000244|PDB:4YZF}.
FT   TURN        394    400       {ECO:0000244|PDB:4YZF}.
FT   HELIX       403    430       {ECO:0000244|PDB:4YZF}.
FT   TURN        431    433       {ECO:0000244|PDB:4YZF}.
FT   HELIX       437    454       {ECO:0000244|PDB:4YZF}.
FT   HELIX       466    481       {ECO:0000244|PDB:4YZF}.
FT   HELIX       486    506       {ECO:0000244|PDB:4YZF}.
FT   HELIX       509    515       {ECO:0000244|PDB:4YZF}.
FT   HELIX       518    546       {ECO:0000244|PDB:4YZF}.
FT   HELIX       570    593       {ECO:0000244|PDB:4YZF}.
FT   STRAND      594    597       {ECO:0000244|PDB:4YZF}.
FT   HELIX       599    607       {ECO:0000244|PDB:4YZF}.
FT   HELIX       609    623       {ECO:0000244|PDB:4YZF}.
FT   STRAND      655    657       {ECO:0000244|PDB:4YZF}.
FT   HELIX       663    666       {ECO:0000244|PDB:4YZF}.
FT   HELIX       668    689       {ECO:0000244|PDB:4YZF}.
FT   HELIX       703    718       {ECO:0000244|PDB:4YZF}.
FT   HELIX       728    735       {ECO:0000244|PDB:4YZF}.
FT   HELIX       761    780       {ECO:0000244|PDB:4YZF}.
FT   HELIX       785    799       {ECO:0000244|PDB:4YZF}.
FT   HELIX       804    813       {ECO:0000244|PDB:4YZF}.
FT   HELIX       823    827       {ECO:0000244|PDB:4YZF}.
FT   TURN        828    831       {ECO:0000244|PDB:4YZF}.
FT   HELIX       832    850       {ECO:0000244|PDB:4YZF}.
FT   HELIX       854    858       {ECO:0000244|PDB:4YZF}.
FT   HELIX       859    873       {ECO:0000244|PDB:4YZF}.
FT   TURN        875    877       {ECO:0000244|PDB:4YZF}.
FT   TURN        880    882       {ECO:0000244|PDB:4YZF}.
FT   HELIX       883    886       {ECO:0000244|PDB:4YZF}.
SQ   SEQUENCE   911 AA;  101792 MW;  35EC3EE7AFF27D2F CRC64;
     MEELQDDYED MMEENLEQEE YEDPDIPESQ MEEPAAHDTE ATATDYHTTS HPGTHKVYVE
     LQELVMDEKN QELRWMEAAR WVQLEENLGE NGAWGRPHLS HLTFWSLLEL RRVFTKGTVL
     LDLQETSLAG VANQLLDRFI FEDQIRPQDR EELLRALLLK HSHAGELEAL GGVKPAVLTR
     SGDPSQPLLP QHSSLETQLF CEQGDGGTEG HSPSGILEKI PPDSEATLVL VGRADFLEQP
     VLGFVRLQEA AELEAVELPV PIRFLFVLLG PEAPHIDYTQ LGRAAATLMS ERVFRIDAYM
     AQSRGELLHS LEGFLDCSLV LPPTDAPSEQ ALLSLVPVQR ELLRRRYQSS PAKPDSSFYK
     GLDLNGGPDD PLQQTGQLFG GLVRDIRRRY PYYLSDITDA FSPQVLAAVI FIYFAALSPA
     ITFGGLLGEK TRNQMGVSEL LISTAVQGIL FALLGAQPLL VVGFSGPLLV FEEAFFSFCE
     TNGLEYIVGR VWIGFWLILL VVLVVAFEGS FLVRFISRYT QEIFSFLISL IFIYETFSKL
     IKIFQDHPLQ KTYNYNVLMV PKPQGPLPNT ALLSLVLMAG TFFFAMMLRK FKNSSYFPGK
     LRRVIGDFGV PISILIMVLV DFFIQDTYTQ KLSVPDGFKV SNSSARGWVI HPLGLRSEFP
     IWMMFASALP ALLVFILIFL ESQITTLIVS KPERKMVKGS GFHLDLLLVV GMGGVAALFG
     MPWLSATTVR SVTHANALTV MGKASTPGAA AQIQEVKEQR ISGLLVAVLV GLSILMEPIL
     SRIPLAVLFG IFLYMGVTSL SGIQLFDRIL LLFKPPKYHP DVPYVKRVKT WRMHLFTGIQ
     IICLAVLWVV KSTPASLALP FVLILTVPLR RVLLPLIFRN VELQCLDADD AKATFDEEEG
     RDEYDEVAMP V
//
